Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 3039-3042

  Li, Youjia ^a,b   Qin, Li ^a   Peng, Nanzheng ^a   Liu, Guangjie ^a,b   Zhao, Siting ^a   He, Zhengxiang ^a   Chen, Xiaoping ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; INDINAVIR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; GROWTH INHIBITION; MALARIA; NONHUMAN; PLASMODIUM CYNOMOLGI; PLASMODIUM KNOWLESI; PRIORITY JOURNAL; RHESUS MONKEY; TREATMENT DURATION;

ANIMALS; ANTIMALARIALS; HIV PROTEASE INHIBITORS; INDINAVIR; MACACA MULATTA; PLASMODIUM CYNOMOLGI; PLASMODIUM KNOWLESI; SAQUINAVIR;

EID: 79956331996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00085-11     Document Type: Article

References (25)

1. Andrews, K. T., et al. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648.
2. Barry, M., F. Mulcahy, C. Merry, S. Gibbons, and D. Back. 1999. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet. 36:289-304.
3. Cox-Singh, J., et al. 2008. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis. 46:165-171.
4. Dorsey, B. D., et al. 1994. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
5. Duval, L., et al. 2009. Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One 4:e5520.
6. Eagling, V. A., D. J. Back, and M. G. Barry. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190-194.
7. FDA. 2005. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, p. 7. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf.
8. Gallagher, M., et al. 2005. The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. AIDS 19:1849-1855. (Pubitemid 41546604)
9. Garcia, L. S. 2010. Malaria update for the clinical microbiology laboratory: a new species, Plasmodium knowlesi, and new diagnostic tests. Clin. Microbiol. Newsl. 32:127-133.
10. Grimwade, K., et al. 2004. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18:547-554. (Pubitemid 38365884)
11. He, Z., L. Chen, J. You, L. Qin, and X. Chen. 2009. Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism. Exp. Parasitol. 123:122-127.
12. He, Z., et al. 2008. Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob. Agents Chemother. 52:2653-2656.
13. Hobbs, C. V., et al. 2009. HIV protease inhibitors inhibit the development of preerythrocytic-stage Plasmodium parasites. J. Infect. Dis. 199:134-141.
14. Jongwutiwes, S., C. Putaporntip, T. Iwasaki, T. Sata, and H. Kanbara. 2004. Naturally acquired Plasmodium knowlesi malaria in human, Thailand. Emerg. Infect. Dis. 10:2211-2213.
15. Lek-Uthai, U., et al. 2008. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob. Agents Chemother. 52:2435-2441.
16. Li, X., et al. 2011. Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. Parasitol. Res. [Epub ahead of print.] doi:10.1007/s00436-011-2427-Z.
17. Parikh, S., et al. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
18. Peatey, C. L., et al. 2010. Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors. Antimicrob. Agents Chemother. 54:1334-1337.
19. Roberts, N. A., et al. 1990. Rational design of peptide-based HIV proteinase-inhibitors. Science 248:358-361.
20. Savarino, A., R. Cauda, and A. Cassone. 2005. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors. J. Infect. Dis. 191:1381-1382.
21. Skinner-Adams, T. S., K. T. Andrews, L. Melville, J. McCarthy, and D. L. Gardiner. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762.
22. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
23. Tripathi, R., D. Mishra, A. Rizvi, and C. Singh. 2007. Evaluation of some adamantane-based synthetic trioxanes against Plasmodium knowlesi in rhesus monkeys. Life Sci. 81:1544-1548. (Pubitemid 350060925)
24. Waters, A. P., D. G. Higgins, and T. F. McCutchan. 1993. Evolutionary relatedness of some primate models of Plasmodium. Mol. Biol. Evol. 10:914-923.
25. WHO. 2010. World malaria report 2010, p. xii. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241564106- eng.pdf.